Eric Low
@EricLow71
Followers
841
Following
4K
Media
2
Statuses
1K
Recommendations on diagnosis and initial treatment of patients with transplant-eligible high-risk multiple myeloma by the British Society of Haematology/UK Myeloma Society https://t.co/pRIcPEEUwr
@MyMKaiser
@DrSStern
@JennerMatthew
@UKMyelomaSoc
1
29
67
Delighted that the @BritSocHaem @UKMyelomaSoc Good Practice Paper on the treatment of high risk transplant-eligible myeloma is now published. Many thanks to @MyMKaiser for his great input. #mmsm British Journal of Haematology | Wiley Online Library
onlinelibrary.wiley.com
Patients with newly diagnosed high-risk multiple myeloma have an ongoing unmet need with current standard-of-care ‘one-size-fits-all’ treatment concepts in form of early relapse and short overall...
1
11
30
Legendary @f2harrell is back at Consilium next week! Sign up here for the talk https://t.co/pxT3HfLoTL
@PotardDechaine @EricLow71 @DrAmandaAdler @david_colquhoun @bogdienache @rarediseaseuk @ResurgeQuality @Richard_D_Riley @vandy_biostat @BabakWork
0
9
22
Great job @EMA_News @HAImedicines @TranspariMED @Meds_Alliance! Learn more here https://t.co/L0K4EkHO2T
@nogracias_eu @RevuePrescrire @ISRCTN @METRICStanford @Marguerite_OR @Jhickmana @EricLow71 @GustavNilsonne @NDevito1
0
2
4
An exciting clinical research fellow in haematology post now open at UK National Amyloidosis Centre and UCLH amyloidosis/MGCS trials clinic - see #nhsjobs - 2-3 yrs with opportunities to do a PhD at UCL. @OSociety @BritSocHaem @EHA_Hematology @ASH_hematology @LinkedIn
0
12
19
Everyone must come! Great science, great city, great food and you get to hang out with cool #mmsm Canadian colleague hosts :) we look forward to welcoming everyone.
0
3
16
Last chance for the #myeloma MRI quiz...
Another leap for quality-controlled WB-MRI for #myeloma . Huge opportunity for better imaging data in trials and their analysis. Amazing collaboration @CTRUmyeloma , thanks @JanssenEMEA @bmsnews for support. Interested in myeloma WB-MRI? see poll tweetorial below 👇 1/10
0
3
10
Join us for a special event to depict HTA methodology and celebrate the legacy of Dr.Eli Gajraj. Sign up here: https://t.co/2f5W0wzmiL
@FrancoisMaignen @JacolineBouvy @SirAndrewDillon @dollendorf @OortwijnW @decide_health @NICESciAdvice @EUnetHTA @EricLow71 @pilarpinilladom
0
7
5
Many thanks, very kind. Deeply feel we should discuss the value of extended upfront risk molecular diagnostic tests more in #myeloma , not only price. We might find that they will help allocate other rare resources like imaging or MRD tests throughout treatment phases better.
Saving the best till last! Love @MyMKaiser talk at #ims23, Importance of co-occurrence of HRCA and relevance of GEP. We have the tools but we seem unable to translate and adopt. Also need to move from understanding biology to novel therapeutic strategies for truly HR MM!
0
8
21
Don't read? Well, here is the podcast:
labiotech.eu
On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp.
$50 billion a year is spent on failed cancer drug development by the pharma industry. Our new paper is a case study on what goes wrong. @consiliumsci @Jhickmana
https://t.co/jdkIdFpZae
1
2
22
Join Consilium on June 16th for a talk from our brilliant AdBoard member Jack Scannell. Sign up here: https://t.co/PLHMMGDBH9
@Jhickmana @rkessler05 @RevuePrescrire @david_colquhoun @LSEHealthPolicy @HealthSenseUK @TranspariMED @HAImedicines @EricLow71 @Anticancerfund
0
4
4
$50 billion a year is spent on failed cancer drug development by the pharma industry. Our new paper is a case study on what goes wrong. @consiliumsci @Jhickmana
https://t.co/jdkIdFpZae
jamanetwork.com
This cross-sectional study examines the costs generated in clinical trials, using the research and development studies of 16 insulin-like receptor-1 inhibitors in cancer, none of which was approved...
8
70
241
If you missed a brilliant talk by @DrDavidHealy at Consilium, watch here https://t.co/aar6sUrLeM
@riotscience_wlv @UKRIO @uaem @Jhickmana @eturnermd1 @EricLow71 @NaudetFlorian @susan_bewley @pash22 @HealthSenseUK @pssd_awareness @cheesyredrocket @PatrickChance @PatientStormDoc
1
10
15
Join to learn the results of the Consilium’s @MyelomaEurope funded project on QoL in multiple myeloma trials @Care4Access @KateEMor_ @drkevinknopf @MyMKaiser @FrancoisMaignen @EricLow71 @MyelomaUK @patvocates @Jhickmana @peterbachmd @AaronGoodman33 @VincentRK @pash22 @IMFmyeloma
1
6
5
If you missed an excellent talk on multi-modal cancer screening tests by @paulpharoah last week, watch here https://t.co/OxdAZzmUdJ
@ecancer @drkevinknopf @oncology_bg @EAEisenhauer @MyMKaiser @EricLow71 @EuropeanCancer @CRUK_Policy
0
2
4
If you missed an excellent live debate organised by @TranspariMED on how the UK trial transparency system can be implemented in other countries, watch here https://t.co/ZciLVwEo2w
@cmarctaylor @Strech_Da @NDevito1 @HRA_Latest @matt_westmore @berlinnovation @EricLow71 @Jhickmana
0
5
6
Will be very interesting to see how this will work in practice - a fantastic, extremely scalable technology. And of course hoping #myeloma patients may be included as well! @BioNTech_Group @NCRI_partners #MMsm
https://t.co/7MSAAqCCHX
ft.com
Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS
0
4
10
5 yrs into Optimum (MUK9) trial still going strong @MyMKaiser @CTRUmyeloma @MyelomaUK #UKMRA @UHNM_NHS kudos goes to myeloma experts brain collaboratively together.
2
3
14
OPTIMUM MUK9 @MyMKaiser: Extended 'kitchen sink' approach for ultra high risk #mmsm. Amazing effort & it's paying off. 30-month PFS is 77%. MRD(-) rates sustained from post-ASCT to subsequent time points. Even OS signal very encouraging. #ASH22
1
16
37
Please take a moment and vote for the Amyloidosis Forum.
The Amyloidosis Forum (an ARC partnership) has made it through to the final round of the @IamHeroX DataWorks! Challenge sponsored by @FASEBorg and @NIH. Now we need your help! Vote now to help our #FederatedAnalytics platform win the final round: https://t.co/RYJymoKoLG
0
1
4